Results 121 to 130 of about 1,124 (174)
Some of the next articles are maybe not open access.
Droxidopa in the Management of Hepatorenal Syndrome
Journal of Pharmacy Practice, 2022Purpose Hepatorenal syndrome (HRS) is renal dysfunction associated with the hemodynamic consequences of advanced liver disease and cirrhosis. HRS is associated with a high mortality, and there remain high failure rates with first-line therapy aimed at improving perfusion.
Andrea Bejjani +4 more
openaire +2 more sources
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases
Expert Opinion on Pharmacotherapy, 2019 Introduction: L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson’s ...
Matilde Otero-Losada +2 more
exaly +2 more sources
Six-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension [PDF]
Movement Disorders Clinical Practice, 2019 ABSTRACTBackgroundDroxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment.ObjectiveExamine the real‐world experience of patients taking droxidopa after six months of treatment ...
Italo Biaggioni +2 more
exaly +3 more sources
Droxidopa for orthostatic hypotension
Journal of Hypertension, 2016The systematic review and meta-analysis aims to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension, following its recent approvals in the United States.MEDLINE, EMBASE, PubMed, Cochrane Controlled Trials Register, Web of Science, ProQuest, and the WHO Clinical Trials Registry were searched.
Victoria, Strassheim +3 more
openaire +2 more sources
Pilot Study of Droxidopa With Carbidopa in Adults With ADHD
Journal of Attention Disorders, 2015Objective: We conducted a two-period (open-label and double-blind) pilot investigation of droxidopa, with and without carbidopa, for ADHD. Method: Twenty adult ADHD patients received open-label droxidopa titrated from 200 to 600 mg 3 times per day (TID; Weeks 1-3), then open-label droxidopa plus carbidopa titrated from 25 or 50 mg TID (Weeks 4-6).
Lenard A, Adler, Stephen W, Gorny
openaire +2 more sources
Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome
American Journal of Therapeutics, 2017Background: Postural orthostatic tachycardia syndrome (POTS) is a constellation of signs and symptoms that occur when a patient is upright and relieved by recumbence. Currently, no drugs are labeled for the treatment for POTS.
Mohammed, Ruzieh +4 more
openaire +2 more sources
Droxidopa for neurogenic orthostatic hypotension
Expert Opinion on Orphan Drugs, 2015Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinson’s disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that ...
openaire +1 more source
[Study on the metabolism of droxidopa in humans].
Rinsho shinkeigaku = Clinical neurology, 1995Supplement of the deficient neurotransmitters is one of the most effective therapies for neurodegenerative disorders. For the treatment of Parkinson's disease, L-DOPA therapy has been applied to replace dopamine, and droxidopa (L-threo-3,4-dihydroxyphenylserine) therapy to supply noradrenaline (NA).
W, Maruyama, M, Naoi, H, Narabayashi
openaire +1 more source
Droxidopa approved for neurogenic orthostatic hypotension
American Journal of Health-System Pharmacy, 2014Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire +1 more source